Endocare Inc

Endocare — Merger or Acquisition (November 2008)

52 slides from Endocare's merger presentation, Nov 12, 2008

  1. Slide 1: All-Employee Meeting November 10, 2008

    All-Employee Meeting November 10, 2008

  2. Slide 2: A Strategic Combination to Advance Cryoablation

    A Strategic Combination to Advance Cryoablation Exciting Company Announcement Endocare & Galil Medical Merger

  3. Slide 3: Disclaimer: Forward Looking Statements

    Disclaimer FORWARD LOOKING STATEMENTS Certain matters set forth in this presentation, including statements relating to the merger, such as efficiencies, cost savings, enhanced revenues, growth potential, market profile and financial strength, and the competitive ability and position of the combined

  4. Slide 4: Disclaimer (cont'd)

    Disclaimer (cont'd) IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with the proposed merger with Galil, Endocare, Inc. (the "Company" or "Endocare") intends to file a registration statement on Form S-4 (the "Registration Statement"), which will also include a proxy stateme

  5. Slide 5: What Does This Mean?

    What Does This Mean?

  6. Slide 6: Is This a Merger, an Acquisition, or Other?

    A merger of equals - a marriage of opportunity Goal: bring together the best of both companies Gain widespread acceptance of cryo Enhance technology innovation Increased reach and growth All decisions will be based on these goals Is This a Merger, an Acquisition, or Other?

  7. Slide 7: Vision of the Merger

    Vision of the Merger Two Great Companies... One Great Vision Build a strong future together

  8. Slide 8: Merger Advantages

    Merger Advantages Joining the two companies will allow: the ability to combine resources, making us stronger greater financial resources a larger annual revenue base us to be a stronger international company complimentary technology and a larger patent base the ability to consolidate overhead expens

  9. Slide 9: Who is Galil?

    Who is Galil? Founded in 1996 Complimentary technology to Endocare Corporate headquarters in Yokneam, Israel Includes R&D and manufacturing, etc. Sales offices in Plymouth Meeting, PA and London, England Annual revenues of $28 million in 2007 120+ employees in 4 countries Strong international sales

  10. Slide 10: Why Did the Company Have To Raise Money?

    Ensure adequate funds to invest in our future and provide a bridge to profitability Financial ability to stay focused on: R&D projects and technology innovation Clinical studies to advance acceptance of cryo Business expansion programs Why Did the Company Have To Raise Money?

  11. Slide 11: When Will the Transaction Be Officially Closed?

    Difficult to predict at this early stage Estimate at least 90 - 180 days - Q1 2009 Subject to approvals Stockholders Regulators Must continue to operate as separate, independent companies until closing Do not communicate with counterparts at Galil without prior approval When Will the Transaction Be

  12. Slide 12: What Does This Mean For Endocare?

    What Does This Mean For Endocare?

  13. Slide 13: Leadership

    Leadership Marty Emerson will be CEO Effective at closing Background: Over 20 years of experience in the medical device industry Prior to Galil, was president and CEO of AMS Prior to AMS, held senior roles at Baxter International and Boston Scientific Serves on the board of Wright Medical and Incisi

  14. Slide 14: What About our Name? Public or Private?

    No name changes for either company until close We will evaluate a name change after the close May or may not make a change We will continue to be a public company What About our Name? Public or Private?

  15. Slide 15: Positive Impact on Endocare's Strategic Plan

    Operating losses/cash infusion Larger company Commercialize technology platforms Increase in technology innovation Retention of key employees More employee opportunities International expansion opportunity Galil has significant int'l revenues Clinical research balanced with profits Combined company

  16. Slide 16: What Will be NewCo's Priorities?

    What Will be "NewCo's" Priorities? Expand use and widespread acceptance of cryo Integrate companies post-closing to quickly capitalize on efficiencies Integration Leaders Suzanne Douglass (Endocare) Karen Sarid (Galil) Facilitate further advances in innovation and efficient technology development In

  17. Slide 17: What Will This Mean To Me?

    What Will This Mean To Me?

  18. Slide 18: What About Me and My Job?

    Decisions relating to specific positions have not been made. Projected Officers of NewCo: CEO & President Marty Emerson CFO Michael Rodriguez General Counsel Clint Davis Other decisions communicated as quickly as possible. What About Me and My Job?

  19. Slide 19: Will There Be Job Reductions?

    Will There Be Job Reductions? If reductions are needed, severance will be provided Amount of severance determined by multiple factors Title, tenure, performance, etc. We are committed to full and timely communication when specific decisions are made

  20. Slide 20: Will My Responsibilities Be Same As Before?

    No changes prior to closing Some areas will be consolidated quickly after the closing to realize efficiencies Integration plans and timelines communicated as plans are finalized Will My Responsibilities Be Same As Before?

  21. Slide 21: What if I have Questions?

    Management will communicate frequently We are very open to your questions and concerns Confidential tool will be available to ask questions Weekly newsletter Will provide updated information as available Mini-seminars on change management Suzanne Douglass to conduct Also, weekly "brown bag" lunches

  22. Slide 22: What's Next...

    What's Next... Don't... Panic. Don't... Start looking for a new job. Don't... Hesitate to ask questions. Don't... Communicate with Galil personnel. Do... Embrace change. Do... Maintain a positive attitude. Do... Focus on business as usual. Do... Be excited - our future is bright!

  23. Slide 23: Questions?

    Questions?

  24. Slide 24: Sales Conference Call November 10, 2008

    Sales Conference Call Kevin Quilty Sr. VP, Sales & Marketing November 10, 2008

  25. Slide 25: A Strategic Combination to Advance Cryoablation

    A Strategic Combination to Advance Cryoablation Exciting Company Announcement Endocare & Galil Medical Merger

  26. Slide 26: Disclaimer: Forward Looking Statements

    Disclaimer FORWARD LOOKING STATEMENTS Certain matters set forth in this presentation, including statements relating to the merger, such as efficiencies, cost savings, enhanced revenues, growth potential, market profile and financial strength, and the competitive ability and position of the combined

  27. Slide 27: Disclaimer (cont'd.)

    Disclaimer (cont'd.) IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with the proposed merger with Galil, Endocare, Inc. (the "Company" or "Endocare") intends to file a registration statement on Form S-4 (the "Registration Statement"), which will also include a proxy statem

  28. Slide 28: What Does This Mean?

    What Does This Mean?

  29. Slide 29: Is This a Merger, an Acquisition, or Other?

    A merger of equals - a marriage of opportunity Goal: bring together the best of both companies Gain widespread acceptance of cryo Enhance technology innovation Increased reach and growth All decisions will be based on these goals Is This a Merger, an Acquisition, or Other?

  30. Slide 30: Vision of the Merger

    Vision of the Merger Two Great Companies One Great Vision Build a strong future together

  31. Slide 31: Merger Advantages

    Merger Advantages Joining the two companies will allow: the ability to combine resources, making us stronger greater financial resources a larger annual revenue base us to be a stronger international company complimentary technology and a larger patent base the ability to consolidate overhead expens

  32. Slide 32: Who is Galil?

    Who is Galil? Founded in 1996 Complimentary technology to Endocare Corporate headquarters in Yokneam, Israel Includes R&D and manufacturing, etc. Sales offices in Plymouth Meeting, PA and London, England Annual revenues of $28 million in 2007 120+ employees in 4 countries Strong international sales

  33. Slide 33: Why Did the Company Have To Raise Money?

    Ensure adequate funds to invest in our future and provide a bridge to profitability Financial ability to stay focused on: R&D projects and technology innovation Clinical studies to advance acceptance of cryo Business expansion programs Why Did the Company Have To Raise Money?

  34. Slide 34: When Will the Transaction Be Officially Closed?

    Difficult to predict at this early stage Estimate at least 90 - 180 days - Q1 2009 Subject to approvals Stockholders Regulators Must continue to operate as separate, independent companies until closing Do not communicate with counterparts at Galil without prior approval When Will the Transaction Be

  35. Slide 35: What Does This Mean For Endocare?

    What Does This Mean For Endocare?

  36. Slide 36: Leadership

    Leadership Marty Emerson will be CEO Effective at closing Background: Over 20 years of experience in the medical device industry Prior to Galil, was president and CEO of AMS Prior to AMS, held senior roles at Baxter International and Boston Scientific Serves on the board of Wright Medical and Incisi

  37. Slide 37: What About our Name? Public or Private?

    No name changes for either company until close We will evaluate a name change after the close May or may not make a change We will continue to be a public company What About our Name? Public or Private?

  38. Slide 38: Positive Impact on Endocare's Strategic Plan

    Operating losses/cash infusion Larger company Commercialize technology platforms Increase in technology innovation Retention of key employees More employee opportunities International expansion opportunity Galil has significant int'l revenues Clinical research balanced with profits Combined company

  39. Slide 39: What Will be NewCo's Priorities?

    What Will be "NewCo's" Priorities? Expand use and widespread acceptance of cryo Integrate companies post-closing to quickly capitalize on efficiencies Integration Leaders Suzanne Douglass (Endocare) Karen Sarid (Galil) Facilitate further advances in innovation and efficient technology development In

  40. Slide 40: What Will This Mean To Me?

    What Will This Mean To Me?

  41. Slide 41: After the close, will I still report to the same manager?

    After the close, will I still report to the same manager? Post-close management structure in the process of being developed. Good chance you will report to same manager; however, post-closing realignment will be conducted. Once plan is finalized, team will be notified; plans not implemented until af

  42. Slide 42: Will I keep my same territory?

    Between today's announcement and close, territories will not change; Post-close, there may be some realignment of territories. Combined sales organization will be larger than either of our organizations as independent companies. Decisions will be communicated as quickly as possible. Will I keep my s

  43. Slide 43: Will my commission plan change?

    There will be new post-close sales quotas and commission plans. During the period between announcement and close, each company will have separate commission plans. A special transition period incentive plan will be implemented to ensure focus and continuous growth. Will my commission plan change?

  44. Slide 44: Will we sell both products?

    Will we sell both products? If so, will we get commission for both products? Only after the companies are combined, will both products will be offered. Your commission between now and the close will be for sales of Endocare product only. After the closing, training will be provided on the use of bot

  45. Slide 45: If a customer wants to order Galil product from me, can they?

    If a customer wants to order Galil product from me, can they? No. Imperative we remain independent companies between announcement and close. Continue to promote current products and perform sales efforts as done prior to announcement. No integration of sales and marketing activities of two companies

  46. Slide 46: What has been/will be communicated to our customers?

    What has been/will be communicated to our customers? Communication strategy has been developed to inform customers of merger. Company-specific letter being sent to customers of both companies. Endocare's Management Team will be making personal contact with key customers. Submit specific requests to

  47. Slide 47: What should I say to my customers?

    What should I say to my customers? Communicate only information contained within press release and/or prepared letter from Kevin Quilty. Business-as-usual; no changes will take place until closing. Assure customers that once merger is complete, stronger company with powerful product offering.

  48. Slide 48: Can/Should I meet with the Galil sales counterpart?

    Can/Should I meet with the Galil sales counterpart for my territory? Between now and closing of transaction, no communications with Galil personnel. Any communications in advance of close must be authorized, in advance, by transition team. Until transaction officially closes, must continue to operat

  49. Slide 49: What if I have Questions?

    Management will communicate frequently We are very open to your questions and concerns Confidential tool will be available to submit questions/concerns Weekly newsletter - will provide updated information as available What if I have Questions?

  50. Slide 50: What's Next...

    What's Next... Don't... Panic! Don't... Start looking for a new job! Don't... Hesitate to ask questions! Don't... Communicate w/ Galil personnel! Do... Embrace change! Do... Maintain a positive attitude! Do... Stay focused on business as usual! Do... Be excited - our future is bright!

  51. Slide 51: Customer Fact Sheet

    Customer Fact Sheet

  52. Slide 52: Questions?

    Questions?

Endocare — Merger or Acquisition (November 2008) on 6ix